Arrowhead Pharmaceuticals Inc [ARWR] stock prices are up 6.74% to $56.25 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARWR shares have gain 39.06% over the last week, with a monthly amount glided 32.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] stock has seen the most recent analyst activity on June 05, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $31. Previously, BofA Securities started tracking the stock with Buy rating on December 04, 2023, and set its price target to $29. On September 19, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $33 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. SVB Securities downgraded its rating to a Market Perform but $40 remained the price target by the analyst firm on May 12, 2023. SMBC Nikko started tracking with a Outperform rating for this stock on April 26, 2023, and assigned it a price target of $80. In a note dated April 12, 2023, SVB Securities upgraded an Outperform rating on this stock and boosted its target price from $21 to $35.
The stock price of Arrowhead Pharmaceuticals Inc [ARWR] has been fluctuating between $9.57 and $59.15 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] shares were valued at $56.25 at the most recent close of the market. An investor can expect a potential drop of -14.67% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.41 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.23 points at the first support level, and at 50.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.27, and for the 2nd resistance point, it is at 60.29.
Ratios To Look Out For
It’s worth pointing out that Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR]’s Current Ratio is 4.86. Also, the Quick Ratio is 4.86, while the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 9.21, the price to book ratio is 16.38.
Transactions by insiders
Recent insider trading involved Ferrari Mauro, Director, that happened on Nov 28 ’25 when 8750.0 shares were sold. Director, Mauro Ferrari completed a deal on Nov 28 ’25 to buy 8750.0 shares. Meanwhile, Chief Medical Officer Hamilton James C sold 20000.0 shares on Oct 01 ’25.
